Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
Abstract We describe a case of diabetic ketoacidosis (DKA) shortly after the SARS‐CoV‐2 (COVID‐19) vaccination in a 65‐year‐old woman with non–small‐cell lung cancer under a combination treatment of programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhib...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-04-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14352 |
| _version_ | 1817990428063956992 |
|---|---|
| author | Tomonori Makiguchi Takashi Fukushima Hisashi Tanaka Kageaki Taima Shinobu Takayasu Sadatomo Tasaka |
| author_facet | Tomonori Makiguchi Takashi Fukushima Hisashi Tanaka Kageaki Taima Shinobu Takayasu Sadatomo Tasaka |
| author_sort | Tomonori Makiguchi |
| collection | DOAJ |
| description | Abstract We describe a case of diabetic ketoacidosis (DKA) shortly after the SARS‐CoV‐2 (COVID‐19) vaccination in a 65‐year‐old woman with non–small‐cell lung cancer under a combination treatment of programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhibitors. She had no history of diabetic mellitus. A few days after the second shot of COVID‐19 vaccination, she developed DKA. We speculate that the immune‐related adverse event and immunogenicity of vaccination synergistically induced DKA. |
| first_indexed | 2024-04-14T00:59:54Z |
| format | Article |
| id | doaj.art-f88180d6214d451ab79f84a76ab87c4e |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-14T00:59:54Z |
| publishDate | 2022-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-f88180d6214d451ab79f84a76ab87c4e2022-12-22T02:21:28ZengWileyThoracic Cancer1759-77061759-77142022-04-011381220122310.1111/1759-7714.14352Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case reportTomonori Makiguchi0Takashi Fukushima1Hisashi Tanaka2Kageaki Taima3Shinobu Takayasu4Sadatomo Tasaka5Department of Respiratory Medicine Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Endocrinology and Metabolism Hirosaki University Graduate School of Medicine Hirosaki JapanDepartment of Respiratory Medicine Hirosaki University Graduate School of Medicine Hirosaki JapanAbstract We describe a case of diabetic ketoacidosis (DKA) shortly after the SARS‐CoV‐2 (COVID‐19) vaccination in a 65‐year‐old woman with non–small‐cell lung cancer under a combination treatment of programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhibitors. She had no history of diabetic mellitus. A few days after the second shot of COVID‐19 vaccination, she developed DKA. We speculate that the immune‐related adverse event and immunogenicity of vaccination synergistically induced DKA.https://doi.org/10.1111/1759-7714.14352COVID‐19 vaccinationdiabetic ketoacidosisimmune checkpoint inhibitorimmune‐related adverse event |
| spellingShingle | Tomonori Makiguchi Takashi Fukushima Hisashi Tanaka Kageaki Taima Shinobu Takayasu Sadatomo Tasaka Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report Thoracic Cancer COVID‐19 vaccination diabetic ketoacidosis immune checkpoint inhibitor immune‐related adverse event |
| title | Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report |
| title_full | Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report |
| title_fullStr | Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report |
| title_full_unstemmed | Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report |
| title_short | Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report |
| title_sort | diabetic ketoacidosis shortly after covid 19 vaccination in a non small cell lung cancer patient receiving combination of pd 1 and ctla 4 inhibitors a case report |
| topic | COVID‐19 vaccination diabetic ketoacidosis immune checkpoint inhibitor immune‐related adverse event |
| url | https://doi.org/10.1111/1759-7714.14352 |
| work_keys_str_mv | AT tomonorimakiguchi diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport AT takashifukushima diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport AT hisashitanaka diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport AT kageakitaima diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport AT shinobutakayasu diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport AT sadatomotasaka diabeticketoacidosisshortlyaftercovid19vaccinationinanonsmallcelllungcancerpatientreceivingcombinationofpd1andctla4inhibitorsacasereport |